NeuroPace, Inc. (NASDAQ:NPCE) Stock Holdings Increased by Barclays PLC

Barclays PLC increased its stake in shares of NeuroPace, Inc. (NASDAQ:NPCE) by 346.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 20,633 shares of the company’s stock after purchasing an additional 16,007 shares during the quarter. Barclays PLC’s holdings in NeuroPace were worth $144,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Millennium Management LLC raised its stake in shares of NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares in the last quarter. State Street Corp increased its holdings in NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after buying an additional 12,912 shares during the last quarter. Acadian Asset Management LLC raised its position in NeuroPace by 46.0% during the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after acquiring an additional 21,703 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in NeuroPace in the second quarter valued at approximately $257,000. Finally, XTX Topco Ltd grew its position in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after acquiring an additional 8,643 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Wells Fargo & Company cut their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. JPMorgan Chase & Co. raised their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, NeuroPace currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Insider Transactions at NeuroPace

In other news, major shareholder Ltd. Kck sold 4,031 shares of NeuroPace stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74. Following the sale, the insider now owns 5,521,874 shares of the company’s stock, valued at approximately $36,113,055.96. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders have sold 246,239 shares of company stock worth $1,363,038. Insiders own 22.20% of the company’s stock.

NeuroPace Stock Up 4.1 %

NeuroPace stock opened at $12.42 on Wednesday. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. NeuroPace, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $18.15. The firm has a fifty day moving average price of $10.03 and a two-hundred day moving average price of $8.13. The firm has a market cap of $370.71 million, a price-to-earnings ratio of -12.42 and a beta of 2.02.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million during the quarter, compared to analysts’ expectations of $19.33 million. NeuroPace had a negative return on equity of 205.41% and a negative net margin of 36.74%. During the same quarter in the previous year, the firm earned ($0.28) EPS. As a group, analysts forecast that NeuroPace, Inc. will post -1 earnings per share for the current year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.